Cancertrack - Liquid Biopsies - A Powerful Test For Better Management and Monitoring of Cancer Treatments

Conventional means for evaluating status of cancer and treatment response is by radiological follow-up scans every ~3 months, which have radiation exposure risks and necessitate a visit to a specialized facility. Such conventional follow-up is also unable to predict treatment failure or disease progression.

While serum tumor antigens have been described for some cancers, these generally have lower accuracy for prediction of disease progression and do not provide any insight into molecular aspects of the cancer leading to disease progression.

An intelligent liquid biopsy that provides relevant intel on the status of the cancer including early signs of disease progression and the underlying molecular mechanisms can facilitate more effective clinical decision making for better management and improved outcomes.

Custom icon

About Cancertrack™

Cancertrack™ is an advanced minimally invasive blood test which provides real time intel on the status of a malignancy from a safe, simple and quick blood draw.

How does
Cancertrack™ work?

Cancertrack™ profiles molecular features in circulating tumor DNA and circulating tumor RNA and also evaluates ‘Circulating Tumor Cells’ (CTCs) to monitor the disease/recurrence or changes in the tumour characteristics, as often as necessary. Recurrences or disease progression can thus be detected as early as possible and therapy can be adjusted.


Reliable Technology

Cancertrack™ evaluates circulating tumor analytes including DNA, RNA and CTCs, which are known to be present ubiquitously in blood samples in all solid tumors. Several prior clinical studies, including DCG’s own acclaimed studies have shown that Liquid Biopsies have the potential to provide for more effective clinical decision making and management of cancers leading to improved patient outcomes. The principle behind Cancertrack™ is well established and the Cancertrack™ test itself has been validated to stringent international standards.

Clinical Performance

Cancertrack™ has been developed and validated by analysis of more than hundred samples by DCG in large cohort studies. Features of Cancertrack: Multi-coordinate and multidimensional probes to track down DNA / RNA released by cancer cells in the patient’s blood | Unique, unprecedented capability to detect cancerous activity. | Enables real-time rapid response to the dynamic molecular profile of a patient’s cancer. | Safe, simple and cost-effective | Rapid lab result. | Tests all active disease sites. | Limits of detection is 0.1% Mutant Allele Frequency

What can Cancertrack reveal?


Indication of cancerous activity in the body

CTC & Exosomes

Indication of molecular dynamics in real-time


Early relapse detection


Molecular signs of drug resistance


Indication of Loss of Heterozygosity (LOH) + Copy Number Variation (CNV)

Real time monitoring of cancer burden, molecular dynamics, treatment response and emerging treatment resistance.

For all patients who have either been diagnosed with cancer or are receiving anticancer treatments or are in remission*. *Recurrence Monitoring only

Custom icon
How it Works?

Circulating tumor components (CTCs*, DNA and RNA) are isolated from a blood sample and analyzed to determine tumor molecular dynamics and characteristics. (*Recurrence Monitoring only).

Custom icon
Why should I get Checked?

Cancertrack™ provides a detailed insight into the burden of cancer (including signs of recurrence), treatment response and potential innate / emergent drug resistance mechanisms.

Exacta™ is available for all solid organ cancers.

Cancertrack™ provides real-time, accurate, reliable and clinically relevant information, which can assist physicians to make life-saving clinical management decisions more effectively.  Download the brochure and sample report below:

Advantages of Cancertrack™

  • Non-invasive blood test is safe, accurate, simple, and cost-effective
  • Not dependent on the availability of tissue
  • Provides more information than standard tissue biopsy and HPE at diagnosis
  • Extensive coverage of NCCN recommended biomarkers
  • Unencumbered by tumor heterogeneity
  • Provides relevant real-time tumor status
  • Can be easily performed as often as required
  • Ultra-sensitive, precise and accurate

Sample Requirements

Whole Blood in DCGL Tube – 16 to 20 mL
Whole Blood in EDTA Tube – 8 to 10 mL

Turn Around Time (TAT):
10 – 12 days from receipt of the sample

Important Publications

Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors.


Author: Crook T
Datar Cancer Genetics
Published Date: Nov 10, 2020

Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors.


Author: Akolkar D
Datar Cancer Genetics
Published Date: Feb 8, 2021

Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC.


Author: Ranade A
Datar Cancer Genetics
Published Date: July 5, 2019


Cancertrack has been validated clinically on several hundred samples and the process validation meets and exceeds the claimed sensitivity and specificity. cancertrack has a combined sensitivity of 99.28% and a positive predictive value of 100%.

The molecular evolution of the tumour including tumour size and molecular diversity, is a continuous process, which is progressing at enormous speed. There are many strategies and drugs available today that can intercept cancerous growth effectively. Thus, earlier detection of the primary / recurrence / drug resistance is essential for an oncologist to make informed decisions.

Cancertrack should ideally be performed at every important milestone during cancer disease and especially when the tumour has disappeared from conventional imaging / patient is under follow-up for recurrence monitoring.

While Cancertrack is extremely robust and multidimensional, like every molecular diagnostic technique, constraints naturally arising due to biological function in an individual patient may impact performance. However, such events are usually averaged out in sequential testing.